OncoMatch/Clinical Trials/NCT06371040
Safety and Efficacy of CD19-BCMA Targeted CAR-T Therapy for Refractory Generalized Myasthenia Gravis
Is NCT06371040 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments including CD19-BCMA Targeted CAR-T Dose 1 and CD19-BCMA Targeted CAR-T Dose 2 for myasthenia gravis.
Treatment: CD19-BCMA Targeted CAR-T Dose 1 · CD19-BCMA Targeted CAR-T Dose 2 · CD19-BCMA Targeted CAR-T Dose 2 — This study is a single-center, open-label, single-arm, dose-exploration study to evaluate the safety and preliminary effectiveness of CD19-BCMA CAR-T in the treatment of refractory, generalized myasthenia gravis. The study is a dose escalation trial in adult, refractory, systemic MG patients. The Keyboard method will be used to perform dose escalation to explore the maximum tolerated dose (MTD). A total of 12 MG patients who meet the inclusion criteria are expected to be recruited.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Demographics
Prior therapy
Must have received: immunosuppressant
Treatment failed after receiving at least 2 immunosuppressants
Cannot have received: rituximab (rituximab)
received rituximab treatment within 6 months before screening
Cannot have received: tocilizumab (tocilizumab)
received tocilizumab ... within 3 months before screening
Cannot have received: eculizumab (eculizumab)
received ... eculizumab treatment within 3 months before screening
Cannot have received: intravenous human immunoglobulin
received intravenous human immunoglobulin ... within 4 weeks before screening
Cannot have received: plasma exchange
received ... plasma exchange ... within 4 weeks before screening
Cannot have received: immunotherapy
received ... immunotherapy within 4 weeks before screening
Lab requirements
Blood counts
Neutrophil count < 1000/ul, Platelet count < 50000/mm3, Hemoglobin < 8.0g/dl excluded
Kidney function
eGFR < 45 mL/min/1.73 m2 excluded
Liver function
AST or ALT > 3x ULN, total bilirubin > 1.5x ULN excluded
Elevated liver enzymes (AST or ALT > 3x ULN). Total bilirubin >1.5x ULN. eGFR <45 mL/min/1.73 m2. Abnormal PT or INR, or prolonged APTT >1.5x ULN. Neutrophil count <1000cell/ul. Platelet count <50000/mm3. Hemoglobin<8.0g/dl
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06371040 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior rituximab, tocilizumab, eculizumab disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 80 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify